SCHEMBL16382602

SCHEMBL16382602

CO/N=C1\C(=N)Oc2ccccc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.35
MAPK1 P28482 1/20 0.35
ATM Q13315 1/20 0.35
GPR84 Q9NQS5 1/20 0.33
ACHE P22303 1/20 0.32
GSK3A P49840 2/20 0.30
GSK3B P49841 2/20 0.30
CDK5 Q00535 2/20 0.30
CDK5R1 Q15078 2/20 0.30
SETD7 Q8WTS6 1/20 0.30
AURKA O14965 1/20 0.30
AURKB Q96GD4 1/20 0.30
AURKC Q9UQB9 1/20 0.30
CCNB2 O95067 1/20 0.30
CDK1 P06493 1/20 0.30
CCNB1 P14635 1/20 0.30
CCNB3 Q8WWL7 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30
HDAC3 O15379 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16382448 1.00 KDM4E (0.35) KDM4EMAPK1ATMGPR84ACHE
SCHEMBL5196943 0.80 TYMS (0.40) KDM4EMAPK1ATMGPR84ACHE
SCHEMBL5196941 0.80 TYMS (0.40) KDM4EMAPK1ATMGPR84ACHE
SCHEMBL16378826 0.77 KDM4E (0.34) KDM4EMAPK1ATMGPR84ACHE
SCHEMBL7511650 0.76 MEN1 (0.35) KDM4EMAPK1ATMGPR84ACHE
SCHEMBL22057240 0.76 MEN1 (0.35) KDM4EMAPK1ATMGPR84ACHE
SCHEMBL31738409 0.76 MEN1 (0.35) KDM4EMAPK1ATMGPR84ACHE
SCHEMBL16382613 0.76 MEN1 (0.35) KDM4EMAPK1ATMGPR84ACHE
SCHEMBL6654635 0.76 MEN1 (0.35) KDM4EMAPK1ATMGPR84ACHE
SCHEMBL7649928 0.76 MEN1 (0.35) KDM4EMAPK1ATMGPR84ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3699178-A1 PROCESS FOR PREPARING FLUOXASTROBIN Arysta LifeScience Corporation (JP) 2020-08-26 EP disclosed
EP-3019495-B1 PROCESS FOR PREPARING FLUOXASTROBIN ARYSTA LIFESCIENCE CORP (JP) 2020-06-03 EP disclosed
US-9670171-B2 Process for preparing fluoxastrobin ARYSTA LIFESCIENCE CORP (JP) 2017-06-06 US disclosed
US-20160237047-A1 PROCESS FOR PREPARING FLUOXASTROBIN ARYSTA LIFESCIENCE CORP (JP) 2016-08-18 US disclosed
US-9193698-B2 Process for preparing fluoxastrobin ADVINUS THERAPEUTICS, LTD. (IN) 2015-11-24 US disclosed
WO-2015006203-A1 PROCESS FOR PREPARING FLUOXASTROBIN ARYSTA LIFESCIENCE CORPORATION (JP) 2015-01-15 WO disclosed
US-20150011753-A1 PROCESS FOR PREPARING FLUOXASTROBIN ARYSTA LIFESCIENCE CORPORATION (JP) 2015-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237047-A1 PROCESS FOR PREPARING FLUOXASTROBIN CYP4X1, MB, HAO2 KDM4E 1730/4885MAPK1 2463/4885ATM 3231/4885
US-20150011753-A1 PROCESS FOR PREPARING FLUOXASTROBIN CYP4X1, MB, HAO2 KDM4E 1730/4885MAPK1 2463/4885ATM 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.